StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a research note published on Tuesday. The firm issued a sell rating on the biotechnology company's stock.
A number of other equities analysts have also recently issued reports on GNCA. HC Wainwright cut Genocea Biosciences from a buy rating to a neutral rating in a report on Friday, April 29th. Stifel Nicolaus cut Genocea Biosciences from a buy rating to a hold rating in a report on Friday, April 29th. Finally, Robert W. Baird lowered their target price on Genocea Biosciences from $8.00 to $3.00 in a report on Monday, April 11th.
Get Genocea Biosciences alerts:Genocea Biosciences Stock Performance
GNCA opened at $0.01 on Tuesday. The business has a fifty day moving average of $0.02 and a 200 day moving average of $0.50. Genocea Biosciences has a 52-week low of $0.01 and a 52-week high of $2.20. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.35 and a current ratio of 1.35.
Insider Transactions at Genocea Biosciences
In related news, Director Ali Behbahani sold 4,445,093 shares of the company's stock in a transaction dated Wednesday, May 25th. The stock was sold at an average price of $0.08, for a total transaction of $355,607.44. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, Director Ali Behbahani sold 4,445,093 shares of the company's stock in a transaction dated Wednesday, May 25th. The stock was sold at an average price of $0.08, for a total transaction of $355,607.44. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Paul Edward Walker sold 5,931,843 shares of the company's stock in a transaction dated Tuesday, May 24th. The shares were sold at an average price of $0.07, for a total value of $415,229.01. Following the transaction, the insider now directly owns 4,445,093 shares in the company, valued at $311,156.51. The disclosure for this sale can be found here. In the last three months, insiders sold 10,537,612 shares of company stock valued at $781,461. Corporate insiders own 1.61% of the company's stock.Institutional Inflows and Outflows
A hedge fund recently raised its stake in Genocea Biosciences stock. Commonwealth Equity Services LLC grew its position in Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) by 49.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 31,981 shares of the biotechnology company's stock after purchasing an additional 10,576 shares during the period. Commonwealth Equity Services LLC owned approximately 0.06% of Genocea Biosciences worth $37,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 59.25% of the company's stock.
About Genocea Biosciences
(Get Rating)
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Featured Stories
- Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
- Look at Honeywell for a Steady and Diversified Stock
- Why Invest in High-Yield Dividend Stocks?
- Find and Profitably Trade Stocks at 52-Week Lows
- Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
- Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.